{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:36Z","timestamp":1793640576478,"version":"4.5.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13300-026-01915-y","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:02:37Z","timestamp":1790578957000},"page":"1717-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Semaglutide and Sodium\u2013Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis"],"prefix":"10.1007","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct06351748","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shanshan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1915_CR1","unstructured":"American Diabetes Association Professional Practice Committee for D. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S183\u2013S215."},{"issue":"3","key":"1915_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.76","volume":"2","author":"W Weng","year":"2019","unstructured":"Weng W, Tian Y, Kong SX, et al. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. Endocrinol Diabetes Metab. 2019;2(3):e00076.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"12","key":"1915_CR3","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"key":"1915_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679.","journal-title":"Am J Prev Cardiol"},{"key":"1915_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1216160","volume":"14","author":"T Kongmalai","year":"2023","unstructured":"Kongmalai T, Hadnorntun P, Leelahavarong P, et al. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1216160.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1915_CR6","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801."},{"issue":"4","key":"1915_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.560181","volume":"44","author":"G Musso","year":"2012","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375\u201393.","journal-title":"Ann Med"},{"key":"1915_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"key":"1915_CR9","unstructured":"Chinese Society of Diabetes. Guidelines for the prevention and treatment of diabetes in China (2024 edition). Chin J Diabetes. 2024;17(1):16\u2013139."},{"issue":"1","key":"1915_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY. Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):177.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1915_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00125-025-06565-6","volume":"69","author":"JMT Colombijn","year":"2026","unstructured":"Colombijn JMT, de Leijer JF, Visseren FLJ, et al. Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 2026;69(1):36\u201349.","journal-title":"Diabetologia"},{"issue":"5","key":"1915_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1915_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838277","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Luo J, Jiang M, Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13:838277.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1915_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"issue":"5","key":"1915_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahren","year":"2017","unstructured":"Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1915_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1915_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139.","journal-title":"Diabetes Metab"},{"issue":"2","key":"1915_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021;23(2):404\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1915_CR19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1915_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037883","volume":"10","author":"RE Pratley","year":"2020","unstructured":"Pratley RE, Aroda VR, Catarig AM, et al. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open. 2020;10(11):e037883.","journal-title":"BMJ Open"},{"issue":"6","key":"1915_CR21","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1915_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"1915_CR23","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.3390\/jcm11174938","volume":"11","author":"V Bellido","year":"2022","unstructured":"Bellido V, Abreu Padin C, Catarig AM, Clark A, Barreto Pittol S, Delgado E. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective, observational study. J Clin Med. 2022;11(17):4938.","journal-title":"J Clin Med"},{"issue":"11","key":"1915_CR24","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s13300-021-01141-8","volume":"12","author":"P Holmes","year":"2021","unstructured":"Holmes P, Bell HE, Bozkurt K, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study. Diabetes Ther. 2021;12(11):2891\u2013905.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1915_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/a-2007-2061","volume":"131","author":"M Menzen","year":"2023","unstructured":"Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob S. Real-world use of once-weekly semaglutide in type 2 diabetes: results from SemaglUtide Real-world Evidence (SURE) Germany. Exp Clin Endocrinol Diabetes. 2023;131(4):205\u201315.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"7","key":"1915_CR26","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/dom.15045","volume":"25","author":"K Mohammedi","year":"2023","unstructured":"Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023;25(7):1855\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1915_CR27","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/dom.15020","volume":"25","author":"R Napoli","year":"2023","unstructured":"Napoli R, Berra C, Catarig AM, et al. Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab. 2023;25(6):1658\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1915_CR28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","volume":"15","author":"N Rajamand Ekberg","year":"2021","unstructured":"Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark\/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15(5):871\u20138.","journal-title":"Prim Care Diabetes"},{"key":"1915_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108931","volume":"178","author":"G Rudofsky","year":"2021","unstructured":"Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021;178:108931.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1915_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-022-02385-x","volume":"40","author":"BHR Wolffenbuttel","year":"2023","unstructured":"Wolffenbuttel BHR, Brugts MP, Catarig AM, et al. Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study. Adv Ther. 2023;40(3):920\u201333.","journal-title":"Adv Ther"},{"issue":"10","key":"1915_CR31","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/dom.14468","volume":"23","author":"JF Yale","year":"2021","unstructured":"Yale JF, Catarig AM, Grau K, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab. 2021;23(10):2269\u201378.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1915_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s13300-026-01848-6","volume":"17","author":"S Wang","year":"2026","unstructured":"Wang S, Hu P, Shen Z, Chen L. Real-world cohort study of semaglutide in adults with type 2 diabetes using an electronic health records database in Tianjin, China. Diabetes Ther. 2026;17(4):587\u2013602.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1915_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001238","volume":"8","author":"AP McGovern","year":"2020","unstructured":"McGovern AP, Hogg M, Shields BM, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"21","key":"1915_CR34","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.3390\/jcm13216509","volume":"13","author":"JJ Gorgojo-Martinez","year":"2024","unstructured":"Gorgojo-Martinez JJ, Gorriz JL, Cebrian-Cuenca A, Castro Conde A, Velasco Arribas M. Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: a multidisciplinary expert consensus. J Clin Med. 2024;13(21):6509.","journal-title":"J Clin Med"},{"issue":"10","key":"1915_CR35","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1111\/dom.15794","volume":"26","author":"JF Yale","year":"2024","unstructured":"Yale JF, Major-Pedersen A, Catarig AM, Jain R, Menzen M, Holmes P. Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme. Diabetes Obes Metab. 2024;26(10):4429\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1915_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/dom.13896","volume":"22","author":"VR Aroda","year":"2020","unstructured":"Aroda VR, Capehorn MS, Chaykin L, et al. Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1-5 trials. Diabetes Obes Metab. 2020;22(3):303\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1915_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jcjd.2018.09.001","volume":"43","author":"J Carretero G\u00f3mez","year":"2019","unstructured":"Carretero G\u00f3mez J, Ar\u00e9valo Lorido JC, G\u00f3mez Huelgas R, et al. Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study. Can J Diabetes. 2019;43(3):186\u201392.","journal-title":"Can J Diabetes"},{"issue":"2","key":"1915_CR38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clinthera.2019.12.012","volume":"42","author":"O D\u00edaz-Trastoy","year":"2020","unstructured":"D\u00edaz-Trastoy O, Villar-Taibo R, Sifontes-Dub\u00f3n M, et al. GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-world clinical practice. Clin Ther. 2020;42(2):e1\u201312.","journal-title":"Clin Ther"},{"key":"1915_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133229","volume":"431","author":"T Liu","year":"2025","unstructured":"Liu T, Fan Z, Li Y, Xiao B, He C. Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: a propensity score-matched cohort study. Int J Cardiol. 2025;431:133229.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1915_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","volume":"17","author":"A Mousavi","year":"2025","unstructured":"Mousavi A, Shojaei S, Soleimani H, et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17(1):68.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1915_CR41","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","volume":"24","author":"A Shokravi","year":"2025","unstructured":"Shokravi A, Seth J, Mancini GBJ. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol. 2025;24(1):370.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1915_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"10","key":"1915_CR43","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"1915_CR44","doi-asserted-by":"publisher","first-page":"103758","DOI":"10.1016\/j.numecd.2024.09.028","volume":"35","author":"C Tian","year":"2025","unstructured":"Tian C, Yang Z, Zhao S, Zhang P, Li R. Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: a real-world study from FAERS. Nutr Metab Cardiovasc Dis. 2025;35(1):103758.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"1915_CR45","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/dom.12982","volume":"19","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19(10):1353\u201362.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01915-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:03:11Z","timestamp":1793638991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01915-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01915-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bixuan Dong and Zewei Shen are employees of and shareholders in Novo Nordisk A\/S, the sponsors of this study. Shanshan Wang reports no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SCHOLAR was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices. Patient consent was not required as the analyses used retrospective de-identified data without access to personal identifying information. The study protocol and the application for a waiver to the informed consent were approved by the independent ethics committee and institutional review board.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}